AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15791370 — intervention group
Group type: COMPARATOR
Intervention: Standard-care
Number of subjects: 52
Study 11765304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnicotine pharmacotherapy (bupropion, nortriptyline, moclobemide)
Number of subjects: 0
Study 11765304 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement therapy
Number of subjects: 0
Study 9400053 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection
Number of subjects: 100
Study 9400053 — intervention group
Group type: COMPARATOR
Intervention: Gadopentate dimeglumine
Number of subjects: 100
Study 9400053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 100
Study 7894226 — intervention group
Group type: EXPERIMENTAL
Intervention: MNNG (N‐methyl‐N'‐nitro‐N‐nitrosoguanidine) incubation
Number of subjects: 15
Study 7894226 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to environmental tobacco smoke (ETS)
Number of subjects: 15
Study 7894226 — intervention group
Group type: COMPARATOR
Intervention: Control (unventilated room for 8 hours)
Number of subjects: 15
Study 3322848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac 75 mg
Number of subjects: 50
Study 3322848 — intervention group
Group type: COMPARATOR
Intervention: Dipyrone 2 g
Number of subjects: 50
Study 31863284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg alone (Period 1)
Number of subjects: 0
Study 31863284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg with rifampin 600 mg/day (Period 2)
Number of subjects: 0
Study 30653533 — intervention group
Group type: EXPERIMENTAL
Intervention: mavoglurant
Number of subjects: 57
Study 30653533 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 57
Study 28228114 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg TID
Number of subjects: 129
Study 28228114 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 5 mg TID
Number of subjects: 129
Study 28228114 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 1 mg TID
Number of subjects: 129
Study 26379170 — intervention group
Group type: EXPERIMENTAL
Intervention: Annually assessed neuropsychological test scores
Number of subjects: 119
Study 26379170 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood of low walking speed defined using individual-specific distributions of walking speed
Number of subjects: 119
Study 26379170 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood of low computer use defined using individual-specific distributions of computer use
Number of subjects: 119
Study 26379170 — intervention group
Group type: COMPARATOR
Intervention: Normal control (NC) group
Number of subjects: 119
Study 24095005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol HCl 50 mg and adrenaline 0.0225 mg diluted to 1.8 mL by distilled water (Group A)
Number of subjects: 100
Study 24095005 — intervention group
Group type: COMPARATOR
Intervention: Tramadol HCl 50 mg diluted to 1.8 mL by distilled water (Group B)
Number of subjects: 100
Study 21426582 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity of midwifery care model and informational leaflet on managing weight gain in pregnancy
Number of subjects: 0
Study 21426582 — intervention group
Group type: COMPARATOR
Intervention: Routine care plus the same informational leaflet on managing weight gain in pregnancy
Number of subjects: 0
Study 19470838 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin (2,000 mg/day intravenous infusions for 20 days, followed by 1,800 mg/day oral tablets for 140 days)
Number of subjects: 567
Study 19470838 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same regimen as actovegin)
Number of subjects: 567
Study 16960547 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic therapy with valacyclovir (500 mg twice daily for 5 days)
Number of subjects: 80
Study 16960547 — intervention group
Group type: COMPARATOR
Intervention: Suppressive therapy with valacyclovir (500 mg daily)
Number of subjects: 80
Study 16960547 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 80
Study 15561445 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (TN)
Number of subjects: 335
Study 15561445 — intervention group
Group type: COMPARATOR
Intervention: Nicotine nasal spray (NS)
Number of subjects: 335
Study 15561445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TN and NS
Number of subjects: 335
Study 12564655 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG+SU (4 mg rosiglitazone daily plus sulphonylurea)
Number of subjects: 348
Study 12564655 — intervention group
Group type: COMPARATOR
Intervention: SU alone (control group)
Number of subjects: 348
Study 9857665 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifamazid (fixed-dose combination)
Number of subjects: 31
Study 9857665 — intervention group
Group type: COMPARATOR
Intervention: Free simultaneous combination of rifampicin and isoniazid
Number of subjects: 31
Study 8567577 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-resistance exercise protocol consisting of 3 sets of 10 repetition maximum resistances with 1-min rest between sets and exercises
Number of subjects: 7
Study 8567577 — intervention group
Group type: COMPARATOR
Intervention: Control day (nonexercise day)
Number of subjects: 7
Study 2083193 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 120 mg/day
Number of subjects: 0
Study 2083193 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 0
Study 2083193 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 0
Study 2083193 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem titration from 240 to 360 mg/day (q12h)
Number of subjects: 0
Study 2083193 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem titration from 180 to 270 to 360 mg/day (q8h)
Number of subjects: 0
Study 2083193 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching regimen from q8h to q12h
Number of subjects: 0
Study 493866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 5
Study 30714233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination containing polyphenols from Ascophyllum nodosum and Fucus vesiculosus and chromium picolinate
Number of subjects: 65
Study 30714233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination
Number of subjects: 65
Study 28427580 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Graft)
Number of subjects: 1800
Study 28427580 — intervention group
Group type: COMPARATOR
Intervention: DES-PCI (Drug-Eluting Stents)
Number of subjects: 1800
Study 26003637 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69 ST membrane filter
Number of subjects: 17
Study 26003637 — intervention group
Group type: COMPARATOR
Intervention: Traditional AN69 membrane filter
Number of subjects: 17
Study 26003637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AN69 ST and traditional AN69 membrane filters
Number of subjects: 17
Study 26003637 — intervention group
Group type: COMPARATOR
Intervention: Vasoactive drugs usage in group II
Number of subjects: 17
Study 26003637 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation indicators (APTT, PT, INR, PLT)
Number of subjects: 17
Study 26003637 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood coagulation in filters
Number of subjects: 17
Study 26003637 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding complications
Number of subjects: 17
Study 23455193 — intervention group
Group type: COMPARATOR
Intervention: Innovator drug (Singulair)
Number of subjects: 12
Study 23455193 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally manufactured drug (Montiget)
Number of subjects: 12
Study 21300931 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 558
Study 21300931 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 558
Study 20183166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (conducted once a week for three months)
Number of subjects: 0
Study 20183166 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study 20183166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 0
Study 16680955 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed skin grafting
Number of subjects: 54
Study 16680955 — intervention group
Group type: COMPARATOR
Intervention: Early escharectomy
Number of subjects: 54
Study 15515782 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) 5 million IU administered subcutaneously
Number of subjects: 34
Study 15515782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 15515782 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) 5 million IU
Number of subjects: 34
Study 11429627 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (2.6 g kg‐1 carbohydrate)
Number of subjects: 8
Study 11429627 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + CAF (2.6 g kg‐1 carbohydrate + 6 mg kg‐1 caffeine)
Number of subjects: 8
Study 11429627 — intervention group
Group type: EXPERIMENTAL
Intervention: FAT (1.2 g kg‐1 fat with 2000 U I.V. heparin)
Number of subjects: 8
Study 11429627 — intervention group
Group type: EXPERIMENTAL
Intervention: FAT + CAF (1.2 g kg‐1 fat with 2000 U I.V. heparin + 6 mg kg‐1 caffeine)
Number of subjects: 8
Study 9359648 — intervention group
Group type: EXPERIMENTAL
Intervention: Local continuous (LC) injection of carboplatin (30 mg/day for 3, 7 or 14 days)
Number of subjects: 26
Study 9359648 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of carboplatin (210 mg)
Number of subjects: 26
Study 7923492 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal rectopexy (Wells or modified Ripstein's technique)
Number of subjects: 31
Study 7923492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bowel disturbances or anal symptoms)
Number of subjects: 31
Study 7923492 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal rectal procidentia rectopexy
Number of subjects: 31
Study 3432859 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural sleep (100 min)
Number of subjects: 40
Study 3432859 — intervention group
Group type: EXPERIMENTAL
Intervention: High-arousal condition (arousals 1/1 min)
Number of subjects: 40
Study 3432859 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-arousal condition (arousals 1/5 min)
Number of subjects: 40
Study 3432859 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium arousal condition (arousals 1/3 min)
Number of subjects: 40
Study 3432859 — intervention group
Group type: COMPARATOR
Intervention: No sleep
Number of subjects: 40
Study 30142760 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine plus normal saline (group R)
Number of subjects: 50
Study 30142760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine plus dexmedetomidine (group RD)
Number of subjects: 50
Study 27993104 — intervention group
Group type: EXPERIMENTAL
Intervention: T-2 toxin at 0.15, 0.33 and 1.82 mg kg‐1 body weight
Number of subjects: 0
Study 27993104 — intervention group
Group type: EXPERIMENTAL
Intervention: Deoxynivalenol (DON) at 0.13, 0.31 and 1.75 mg kg‐1 body weight
Number of subjects: 0
Study 27993104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mycotoxins (T-2 toxin and DON)
Number of subjects: 0
Study 27993104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest dose of both mycotoxins
Number of subjects: 0
Study 27993104 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of both mycotoxins
Number of subjects: 0
Study 25046787 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L/min of oxygen via nasal cannula
Number of subjects: 400
Study 25046787 — intervention group
Group type: COMPARATOR
Intervention: Approximately 80% supplemental inspired oxygen after tracheal extubation
Number of subjects: 400
Study 23462927 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-containing energy drink (3 mg/kg body mass)
Number of subjects: 16
Study 23462927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22290036 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Stroop task
Number of subjects: 31
Study 22290036 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Stroop task
Number of subjects: 31
Study 18005493 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 326
Study 18005493 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy
Number of subjects: 326
Study 18005493 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused therapy
Number of subjects: 326
Study 16491216 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent blue dye (PBD)
Number of subjects: 94
Study 16491216 — intervention group
Group type: COMPARATOR
Intervention: Gamma probe detection (GPD)
Number of subjects: 94
Study 16491216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PBD and GPD
Number of subjects: 94
Study 12854150 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG (200 IU intramuscularly every 4 weeks from 28 weeks of gestation)
Number of subjects: 151
Study 12854150 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (100 mg orally every day from 28 weeks of gestation until 30 days after labor)
Number of subjects: 151
Study 12854150 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific treatment)
Number of subjects: 151
Study 10868648 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐7 infection
Number of subjects: 52
Study 10868648 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV
Number of subjects: 52
Study 10868648 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐7
Number of subjects: 52
Study 10868648 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV and HHV‐7 co-infection
Number of subjects: 52
Study 10868648 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐6
Number of subjects: 52
Study 9352724 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with centrotemporal spikes
Number of subjects: 40
Study 9352724 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 8174495 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (1 g q 8 h)
Number of subjects: 84
Study 8174495 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside + amoxycillin + clindamycin (C)
Number of subjects: 84
Study 3580237 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam given by infusion
Number of subjects: 0
Study 3580237 — intervention group
Group type: COMPARATOR
Intervention: Midazolam given as hourly intermittent injections
Number of subjects: 0
Study 3580237 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (infusion)
Number of subjects: 0
Study 28870405 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAO plasma levels measured at emergency department admission
Number of subjects: 189
Study 28870405 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAO plasma levels
Number of subjects: 189
Study 28870405 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher age, higher body mass index, diabetes mellitus, chronic kidney disease
Number of subjects: 189
Study 27514751 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistate model to predict HF hospitalization and all-cause mortality
Number of subjects: 3834
Study 27514751 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistate model
Number of subjects: 3834
Study 24684703 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 74
Study 24684703 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal fetal electrocardiogram
Number of subjects: 74
Study 24684703 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrohysterography
Number of subjects: 74
Study 24684703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocodynamometry
Number of subjects: 74
Study 22744141 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent + therapist enhanced milieu teaching (EMT)
Number of subjects: 77
Study 22744141 — intervention group
Group type: COMPARATOR
Intervention: Therapist-only EMT
Number of subjects: 77
Study 20577748 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg daily for 5 days for up to six cycles)
Number of subjects: 260
Study 20577748 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian diathermy (LOD)
Number of subjects: 260
Study 20577748 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 260
Study 20577748 — intervention group
Group type: COMPARATOR
Intervention: LOD
Number of subjects: 260
Study 18930352 — intervention group
Group type: EXPERIMENTAL
Intervention: PENS
Number of subjects: 200
Study 18930352 — intervention group
Group type: EXPERIMENTAL
Intervention: PENS+GCAE
Number of subjects: 200
Study 18930352 — intervention group
Group type: COMPARATOR
Intervention: control-PENS
Number of subjects: 200
Study 18930352 — intervention group
Group type: COMPARATOR
Intervention: control-PENS+GCAE
Number of subjects: 200
Study 16520208 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous enhanced circulation therapy (CECT) system combined with low-dose aspirin (100 mg daily postoperatively)
Number of subjects: 121
Study 16520208 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg per day)
Number of subjects: 121
Study 14743970 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon-targeted tablets of metronidazole
Number of subjects: 6
Study 14743970 — intervention group
Group type: COMPARATOR
Intervention: Immediate release tablets of metronidazole
Number of subjects: 6
Study 10485772 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 50
Study 10485772 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 50
Study 7549809 — intervention group
Group type: COMPARATOR
Intervention: Smokers and patients with oral leukoplakia or erythroplakia
Number of subjects: 0
Study 7549809 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with oral trauma
Number of subjects: 0
Study 7549809 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 0
Study 7549809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 0
Study 2005316 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive dye exposure (black GR and orange 3R)
Number of subjects: 309
Study 2005316 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive dye exposure
Number of subjects: 309
Study 2005316 — intervention group
Group type: EXPERIMENTAL
Intervention: RAST-inhibition tests of black GR
Number of subjects: 309
Study 2005316 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange 3R RAST-inhibition tests
Number of subjects: 309
Study 7022275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release metoprolol 200 mg once daily
Number of subjects: 30
Study 7022275 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation metoprolol 100 mg bd
Number of subjects: 30
Study 31416685 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (70 Gy, with chemotherapy if N1-2)
Number of subjects: 68
Study 31416685 — intervention group
Group type: COMPARATOR
Intervention: TORS plus neck dissection (with or without adjuvant chemoradiotherapy)
Number of subjects: 68
Study 31416685 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 68
Study 31416685 — intervention group
Group type: COMPARATOR
Intervention: TORS plus neck dissection
Number of subjects: 68
Study 28886024 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 25 mg/day with metformin (MET) 2 g/day for 3 months
Number of subjects: 24
Study 28886024 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plac) with metformin (MET) 2 g/day for 3 months
Number of subjects: 24
Study 25845992 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 40 mg/m² and carboplatin AUC 2 with concurrent radiotherapy 66 Gy in 33 fractions
Number of subjects: 10
Study 25845992 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 60 mg/m² and carboplatin AUC 2 with concurrent radiotherapy 66 Gy in 33 fractions
Number of subjects: 10
Study 25845992 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 40 mg/m²
Number of subjects: 10
Study 23453583 — intervention group
Group type: EXPERIMENTAL
Intervention: Tosedostat 120 mg once daily for 6 months
Number of subjects: 76
Study 23453583 — intervention group
Group type: EXPERIMENTAL
Intervention: Tosedostat 240 mg once daily for 2 months followed by 120 mg for 4 months
Number of subjects: 76
Study 21345662 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanols
Number of subjects: 182
Study 21345662 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester
Number of subjects: 182
Study 21345662 — intervention group
Group type: COMPARATOR
Intervention: Plant sterols
Number of subjects: 182
Study 21345662 — intervention group
Group type: COMPARATOR
Intervention: Plant sterol ester
Number of subjects: 182
Study 20187484 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive protocol for intravenous fluid administration (group A, 65 pts)
Number of subjects: 130
Study 20187484 — intervention group
Group type: COMPARATOR
Intervention: Liberal fluid administration policy (group B, 65 pts)
Number of subjects: 130
Study 20187484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study 17363767 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1, EPHX1, and MMP1 polymorphisms
Number of subjects: 282
Study 17363767 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 and EPHX1 single-nucleotide polymorphisms
Number of subjects: 282
Study 17363767 — intervention group
Group type: EXPERIMENTAL
Intervention: EPHX1 His139Arg single-nucleotide polymorphism
Number of subjects: 282
Study 14744971 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (2.7 microg/mm2)
Number of subjects: 190
Study 14744971 — intervention group
Group type: COMPARATOR
Intervention: Bare stent
Number of subjects: 190
Study 11348960 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mL/kg loading dose of perflubron
Number of subjects: 16
Study 11348960 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mL/kg loading dose of perflubron
Number of subjects: 16
Study 9205821 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of JTP-4819 30 mg
Number of subjects: 28